Physician profile
Erin Marshall
NPI 1982717179
$3,999.61
in general payments reported to CMS, 2019-2025
28 companies · $620 in 2025
The $620 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $620 · 2021: $789 · 2022: $295 · 2023: $84.54 · 2024: $949 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,654.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $1,093.22 | 2019-2024 | |
| Tris Pharma INC | $653.09 | 2019-2025 | Dyanavel Xr |
| Corium, LLC | $425.06 | 2021-2025 | Azstarys |
| Glaxosmithkline, LLC. | $374.49 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Takeda Pharmaceuticals U.S.A., INC. | $271.05 | 2020-2021 | |
| Abbott Laboratories | $163.00 | 2024 | Octrode |
| Vertical Pharmaceuticals, LLC | $110.62 | 2019-2025 | Relexxii |
| Supernus Pharmaceuticals, INC. | $97.03 | 2021-2024 | Qelbree, Qelbree |
| Kowa Pharmaceuticals America, INC. | $84.67 | 2024-2025 | Zoryve |
| Cranial Technologies, INC | $82.42 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $75.87 | 2025 | Jornay Pm |
| Shire North American Group INC | $71.79 | 2019 | |
| Genentech USA, INC. | $65.31 | 2019-2021 | |
| Neos Therapeutics, Lp | $64.59 | 2019-2021 | |
| Adlon Therapeutics L.P. | $57.66 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47.32 | 2019-2021 | |
| Pfizer INC. | $45.59 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $28.84 | 2019-2020 | |
| Alk-Abello, INC | $26.09 | 2025 | Neffy |
| Sarepta Therapeutics, INC. | $22.26 | 2019 | |
| Sobi, INC | $21.13 | 2021 | |
| Seqirus USA INC | $20.55 | 2021 | |
| Sanofi Pasteur INC. | $19.71 | 2021 | |
| Verrica Pharmaceuticals INC. | $19.24 | 2024 | Ycanth |
| Lnhc, INC | $17.71 | 2025 | Zelsuvmi |
| Phadia US INC. | $16.24 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.90 | 2020 | |
| Aytu Biopharma, INC. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.